| Date | Title | Description | |
|---|---|---|---|
| 06 Nov 2025 | On P&L | The Company releases the press release related to the first nine months of 2025 financial results | Download |
| 06 Nov 2025 | On P&L | The Company releases the first nine months of 2025 financial results presentation | Download |
| 21 Oct 2025 | On business and financial situation | The Company releases the press release in relation to the announcement of the collaboration with Roche for the manufacture of a new medicine in development | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 02 Apr 2020 | On business and financial situation | ROVI informs on the impact of Covid‑19 on the company’s activities | Download |
| 26 Feb 2020 | Information on P&L | ROVI releases the press release related to the full year 2019 financial results | Download |
| 26 Feb 2020 | Information on P&L | ROVI releases the full year 2019 results presentation | Download |
| 26 Feb 2020 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 26 Feb 2020 | Annual Corporate Governance Report | ROVI releases the 2019 Annual Corporate Governance Report | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |